Please provide your email address to receive an email when new articles are posted on . Combined cataract surgery with iStent inject significantly reduced medication burden in patients with glaucoma.

Please provide your email address to receive an email when new articles are posted on . “Elevated [IOP] is one of the major risk factors for development and progression of POAG [primary open-angle ...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and ...

Multiple 5-, 6-, 7- and 8-Year Real-World Studies Published, Demonstrating Leading Efficacy & Safety Across the Entire Glaucoma Disease Spectrum SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos ...

SLT is emerging as a cost-effective first-line treatment, offering superior intraocular pressure stability compared to traditional eye drops. Minimally invasive glaucoma surgeries, like the iStent ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal ...

NEW ORLEANS -- Patients with glaucoma who were treated with a microstent during cataract surgery retained benefits over traditional surgery at 5 years, a randomized study found. In addition, rate of ...

(RTTNews) - Glaukos Corp. (GKOS) has submitted a supplemental pre-market approval application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with glaucoma, expanding the company’s reach overseas. The green lights under ...

Glaukos secured a new FDA clearance for its miniaturized stent system designed for glaucoma to help drain the inner eye of built-up fluids and normalize intraocular pressure. The company had received ...